Absenteeism. Presenteeism. Canada

Solopreneur. Addiction recovery. Interventions. Family assistance. Organization and HR mentorships.
Virtual meetings Host, Guest, Panelist, Master of Ceremonies.
Company Size (Fulltime employees)
Year of foundation
2017
Partnering Objectives
Please specify your partnering goal
Looking to be hired as a consultant. I have over a half century of lived experience on BOTH sides of the disease.
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Mr. Leo Petrilli
Addiction Recovery Coach AND Mentor 
Functionality

Ananda Devices Canada

Ananda Devices is a biotech company specialized in in vitro assay developments. Leveraging our proprietary nano-organization technology, we have developed physiologically relevant in vitro models that generate predicative responses early on in the compound development processes, thereby accelerating compound discovery and de-risking key developmental investments.
Our nervous on-a-chip technology enables clients to perform drug screening, toxicity and efficacy testing up to 50x faster and 90% more cost-effective. We have 20+ years of experience in neuroscience and tissue engineering, and we have been a developer of unique devices to grow brain, spinal cord and innervated skin models for clients in 12 countries.

Our product:
NeuroHTSTM is a first-in-class high throughput screening (HTS) platform to rapidly cultivate over 3,000 CNS or PNS neurons/plate into physiologically relevant networks.
Its easy-to-use technology requires no additional equipment such as shakers and tubing.
It is compatible with most automation solutions, suitable for both and human/animal models

Our customized services:
Our core technology enables 4 types of innovative assay developments:
-Organization of cell and tissue types for reproducible and physiologically relevant in vitro testing
-Innervation of different tissues
-Miniaturization of existing models to increase throughput and sensitivity
-Development of complex co-culture models to mimic disease on-a-chip

Company Size (Fulltime employees)
Please specify your partnering goal
Looking for new partners and clients
Headquartner in China
Medtech Category
Your Research Tool and Service name
High throughput nervous system on-a-chip platform for compound screening and development
Target client type
Pharmaceutical companies, R and D institutions, contract research services, life science distributors
Slides Deck
(pdf, 2.5MB)
Dr. Doreen Miao
Business Director 
Functionality

ImmunoBiochem Canada

ImmunoBiochem is an immuno-oncology biopharmaceutical company that has developed a disruptive approach to targeting unique proteins amplified in cancer secretomes. These targets are secreted from cancer cells and accumulate in tumors, but not in normal tissues, and are constantly recycled in the tumor microenvironment. This novel approach enables the selective and efficacious delivery of immunomodulatory and chemotherapeutic payloads into relevant subsets of cells within the tumor microenvironment, including tumor cells, immune cells and tumor-supporting stroma.
ImmunoBiochem’s IMB-213I candidate delivers a potent innate immune system agonist for the treatment of highly heterogeneous solid tumors, such as TNBC, pancreatic and ovarian cancers.
ImmunoBiochem's IMB-212 candidate delivers a potent cytotoxic payload into difficult-to-treat solid tumors, particularly where no suitable surface targets and no biologics are available.
Company Size (Fulltime employees)
Please specify your partnering goal
Opportunities for collaborations and joint development
Headquartner in China
Assets Information 1
IMB-213I|Novel Immunomodulatory Antibody Conjugate|Solid Tumors|
Assets Information 2
IMB-212|ADC against a novel cancer secretome-based target|Solid Tumors|
Biotech/Pharma Asset Stage
Dr. Anton Neschadim
CEO 
Functionality

Innovate Calgary Canada

University of Calgary based accelerator
Company Size (Fulltime employees)
Year of foundation
2019
Please specify your partnering goal
looking for partners who are interested in investing/assessing discovery stage technologies, and potentially can partner with our accelerator as CSO
Headquartner in China
Assets Information 1
||neuropathic pain|US, UK, CA, DE, FR
Biotech/Pharma Asset Stage
Dr. Morgan Guo
IPM 
Functionality

Kymeris therapeutics Inc Canada

Kymeris has invented a revolutionary, live-cell based technology platform which delivers into the tumor micro-environment and activates there multiple therapeutic agents - including ligands, cytokines, and antibodies. Efficacy of anti-cancer action has been shown in 5 separate solid cancer indications with reduction in tumour size averaging 80% - but in many cases showing complete eradication. This game changing approach is of particular value to companies with proprietary molecules that are looking for safe and effective vectoring into tumors, and with whom we might partner.
Company Size (Fulltime employees)
Year of foundation
2016
Please specify your partnering goal
Out licensing
Headquartner in China
Biotech/Pharma Category
Mr. Richard McCrae
President & CEO 
Functionality

Lumira Ventures Canada

Lu Han
VC 

Next Pharma Inc. Canada

Next Pharma Inc. (NPI) is a biotechnology company headquartered in Toronto, Canada, focused on developing and commercializing products for early detection, diagnosis, and monitoring of the recurrence of Cancer and COVID-19 disease.
NPI is headquartered in Toronto, Ontario, Canada and will globally distribute and commercialize its AABH based diagnostic tests. NPI’s diagnostic tests are regarded as revolutionary as they can help to diagnose cancer at an early stage using a blood serum with high sensitivity/high specificity, fast turnaround (within 7 hours), are relatively inexpensive and are non-invasive.
Company Size (Fulltime employees)
Year of foundation
2016
Please specify your partnering goal
Shareholder, and/or Partnership, and /or Profit sharing
Headquartner in China
Medtech Category
Medtech Information 1
NPI-Cancer Detection Blood Test|ELISA Kit|Canada
Medtech Development Stage
Dr. MAHMOOD MAHMOOD
Aspartyl (Asparaginyl) β Hydroxylase (AABH), Cancer Biomarker, Companion Imaging, and Diagnostic Strategy 
Functionality

Sixty Degree Capital Canada

Sixty Degree Capital Inc. is a Toronto based venture capital investor with US$200MM+ under management investing across North America and Asia. We are dedicated to building strong, long-term relationships with our partners and investors within our industries of focus. Our Toronto office has been actively investing in Healthcare related sectors in the past several years. By partnering with top tier lead investors such as Lumira Ventures, Versant Ventures, Google Ventures, iNovia Capital etc., we have deployed our capital into some exciting North American companies including Schrödinger (Drug discovery platform), Turnstone Biologics and Northern Biologics (Immuno Oncology therapeutics), as well as Antios Therapeutics (HBV innovative therapy). As a growth to late stage investor, our initial cheque size ranges from USD 3 to 5m with reserve of USD 10~20m.
Year of foundation
2017
Partnering Objectives
Headquartner in China
Yatong Li
Principal 
Functionality

WPD Pharmaceuticals Canada

WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust drug development pipeline with a focus on melanoma, brain cancer, leukemia, and pancreatic cancer. Notably, these funds do not include $14 million USD in grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland.

With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically positioned to enter the market with blockbuster potential.
Company Size (Fulltime employees)
Year of foundation
2017
Headquartner in China
Mariusz Olejniczak
CEO 
Functionality

全球药物商业化中心 Canada

总部加拿大温哥华的VC机构,负责把海外投资的项目引进国内商业化落地
Website:
www.gdcccn.com
Partnering Objectives
Headquartner in China
悦辰 韩
项目总监